Published on 15 Nov 2022 on Zacks via Yahoo Finance
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TherapeuticsMD (TXMD) came out with a quarterly loss of $3.13 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $5.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -53.43%. A quarter ago, it was expected that this woman's health care product company would post a loss of $3.04 per share when it actually produced a loss of $2.15, delivering a surprise of 29.28%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.